Research Analysts Offer Predictions for DexCom, Inc.’s FY2017 Earnings (DXCM)
DexCom, Inc. (NASDAQ:DXCM) – Stock analysts at Leerink Swann increased their FY2017 EPS estimates for DexCom in a research note issued to investors on Thursday. Leerink Swann analyst D. Antalffy now forecasts that the medical device company will post earnings of ($0.76) per share for the year, up from their prior forecast of ($0.86). Leerink Swann has a “Buy” rating and a $57.00 price objective on the stock. Leerink Swann also issued estimates for DexCom’s Q1 2018 earnings at ($0.13) EPS, Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.09) EPS, Q4 2018 earnings at ($0.07) EPS, FY2018 earnings at ($0.40) EPS, FY2019 earnings at ($0.16) EPS, FY2020 earnings at $0.06 EPS and FY2021 earnings at $0.31 EPS.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/research-analysts-offer-predictions-for-dexcom-inc-s-fy2017-earnings-dxcm/1682173.html.
A number of other research firms have also weighed in on DXCM. Barclays PLC reissued an “equal weight” rating and issued a $60.00 price objective (down from $76.00) on shares of DexCom in a research report on Thursday, September 28th. Citigroup Inc. lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 28th. Zacks Investment Research raised shares of DexCom from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. BMO Capital Markets reiterated a “buy” rating and set a $105.00 price objective on shares of DexCom in a research note on Thursday, July 13th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $78.00 price objective (down from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $70.69.
Shares of DexCom (NASDAQ:DXCM) opened at $49.12 on Monday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84.
In other DexCom news, EVP Andrew K. Balo sold 3,244 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $71.18, for a total value of $230,907.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $69.77, for a total transaction of $418,620.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,208 shares of company stock worth $1,597,567. Company insiders own 1.70% of the company’s stock.
Large investors have recently bought and sold shares of the business. Advisor Group Inc. boosted its holdings in DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares during the last quarter. IFP Advisors Inc boosted its holdings in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 568 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its holdings in DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after purchasing an additional 9 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after purchasing an additional 250 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 354 shares during the period.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.